MGC Pharmaceuticals Ltd.
PDMR Notification
03 February 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Person Discharging Managerial Responsibilities (PDMR) has dealt with shares in MGC Pharma, and this notification is made in accordance with UK Market Abuse Regulations.
The shares the subject of this notice were sold by a PDMR who in May 2021, sold her business, MediCaNL Inc, a pharmaceutical research company, to MGC Pharma, and which is now a wholly owned subsidiary of the Company. Details of the MedicaNL transaction are detailed in MGC Pharma's ASX announcement on 22 April 2021, a copy of which can be found at the following URL:
https://www.asx.com.au/asxpdf/20210422/pdf/44vrj4zvy8ztjr.pdf
The PDMR subsequently sold a portion of the vendor consideration shares received under the acquisition terms, in order to satisfy personal capital gains tax liabilities which arose from the PDMR's sale of MediCaNL Inc to MGC Pharma.
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Nadya Lisovoder | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Leading CRO | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Disposal of Shares | |||
| (d) | Currency | Price | Volume | Total | |
| | 1. AUD 2. AUD 3. AUD | $0.048 $0.050 $0.058 | 934,547 7,717,996 13,442,365 | $44,858 $387,443 $779,657 | |
| | Aggregated information | ||||
| | AUD | $0.055 | 22,094,908 | $1,211,959 | |
| (e) | Date of transaction
| 1. 2021-09-01 2. 2021-09-03 3. 2021-09-30 | |||
| (f) | Place of transaction
| Australian Stock Exchange | |||
--Ends--
Authorised for release by the Executive Chair, for further information please contact:
| MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 | MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 |
| UK Broker - Turner Pope Andy Thacker +44 203 657 0050 | UK PR Advisors - Tavistock Charles Vivian / Tim Pearson +44 207 920 3150
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
